Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

@inproceedings{Bertrand2015ImmuneRA,
  title={Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis},
  author={Anne Bertrand and Marie Kostine and Thomas Barnetche and M E Truchetet and Thierry Schaeverbeke},
  booktitle={BMC medicine},
  year={2015}
}
BACKGROUND Targeting CTLA-4 is a recent strategic approach in cancer control: blocking CTLA-4 enhances an antitumor immunity by promoting T-cell activation and cytotoxic T-lymphocyte proliferation. This induction of a tolerance break against the tumor may be responsible for immune-related adverse events (irAEs). Our objective was to assess the incidence and nature of irAEs in oncologic patients receiving anti-CTLA-4 antibodies (ipilimumab and tremelimumab). METHODS A systematic search of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS
72 Citations
140 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 72 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 140 references

Similar Papers

Loading similar papers…